{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:17:38Z","timestamp":1740107858922,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T00:00:00Z","timestamp":1577318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T00:00:00Z","timestamp":1577318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10157-019-01827-1","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T03:02:20Z","timestamp":1577329340000},"page":"369-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of renin\u2013angiotensin system blockade on graft survival and cardiovascular disease in kidney transplant recipients: retrospective multicenter study in Japan"],"prefix":"10.1007","volume":"24","author":[{"name":"The Japan Academic Consortium of Kidney Transplantation (JACK) Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9590-6187","authenticated-orcid":false,"given":"Akihiro","family":"Tsuchimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9190-4600","authenticated-orcid":false,"given":"Kosuke","family":"Masutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaneyasu","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Matsukuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Unagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Kakuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Okumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanari","family":"Kitazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,26]]},"reference":[{"key":"1827_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1600-6143.2008.02519.x","volume":"9","author":"ZM El-Zoghby","year":"2009","unstructured":"El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527\u201335.","journal-title":"Am J Transplant"},{"key":"1827_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73\u2013877.","journal-title":"Ann Intern Med"},{"key":"1827_CR3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin\u2013angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67:728\u201341.","journal-title":"Am J Kidney Dis"},{"key":"1827_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/ndt\/gfx072","volume":"33","author":"I Nistor","year":"2018","unstructured":"Nistor I, De Sutter J, Drechsler C, Goldsmith D, Soler MJ, Tomson C, et al. Effect of renin-angiotensin-aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33:12\u201322.","journal-title":"Nephrol Dial Transplant"},{"key":"1827_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"1827_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"1827_CR7","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","volume":"285","author":"LY Agodoa","year":"2001","unstructured":"Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719\u201328.","journal-title":"JAMA"},{"key":"1827_CR8","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1681\/ASN.2006101081","volume":"18","author":"DM Kent","year":"2007","unstructured":"Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in non-diabetic kidney disease. J Am Soc Nephrol. 2007;18:1959\u201365.","journal-title":"J Am Soc Nephrol"},{"key":"1827_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1056\/NEJMoa053107","volume":"354","author":"FF Hou","year":"2006","unstructured":"Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131\u201340.","journal-title":"N Engl J Med"},{"key":"1827_CR10","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1046\/j.1523-1755.2000.00239.x","volume":"58","author":"D Hernandez","year":"2000","unstructured":"Hernandez D, Lacalzada J, Salido E, Linares J, Barragan A, Lorenzo V, et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int. 2000;58:889\u201397.","journal-title":"Kidney Int"},{"key":"1827_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/TP.0b013e3181bf13d9","volume":"89","author":"AB Amara","year":"2010","unstructured":"Amara AB, Sharma A, Alexander JL, Alfirevic A, Mohiuddin A, Pirmohamed M, et al. Randomized controlled trial: lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy. Transplantation. 2010;89:104\u201314.","journal-title":"Transplantation"},{"key":"1827_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/ndt\/gfp581","volume":"25","author":"T Philipp","year":"2010","unstructured":"Philipp T, Martinez F, Geiger H, Moulin B, Mourad G, Schmieder R, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant. 2010;25:967\u201376.","journal-title":"Nephrol Dial Transplant"},{"key":"1827_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1681\/ASN.2012080777","volume":"24","author":"HN Ibrahim","year":"2013","unstructured":"Ibrahim HN, Jackson S, Connaire J, Matas A, Ney A, Najafian B, et al. Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol. 2013;24:320\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"1827_CR14","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/TP.0b013e3182827a43","volume":"95","author":"E Paoletti","year":"2013","unstructured":"Paoletti E, Bellino D, Marsano L, Cassottana P, Rolla D, Ratto E. Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial. Transplantation. 2013;95:889\u201395.","journal-title":"Transplantation"},{"key":"1827_CR15","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1111\/ajt.13384","volume":"15","author":"DA Mandelbrot","year":"2015","unstructured":"Mandelbrot DA, Alberu J, Barama A, Marder BA, Silva HT Jr, Flechner SM, et al. Effect of ramipril on urinary protein excretion in maintenance renal transplant patients converted to sirolimus. Am J Transplant. 2015;15:3174\u201384.","journal-title":"Am J Transplant"},{"key":"1827_CR16","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S2213-8587(15)00368-X","volume":"4","author":"GA Knoll","year":"2016","unstructured":"Knoll GA, Fergusson D, Chasse M, Hebert P, Wells G, Tibbles LA, et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:318\u201326.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1827_CR17","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1681\/ASN.2006050543","volume":"17","author":"G Opelz","year":"2006","unstructured":"Opelz G, Zeier M, Laux G, Morath C, Dohler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol. 2006;17:3257\u201362.","journal-title":"J Am Soc Nephrol"},{"key":"1827_CR18","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1681\/ASN.2005090955","volume":"17","author":"G Heinze","year":"2006","unstructured":"Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17:889\u201399.","journal-title":"J Am Soc Nephrol"},{"key":"1827_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/ndt\/gfr276","volume":"27","author":"D Hernandez","year":"2012","unstructured":"Hernandez D, Muriel A, Abraira V, Perez G, Porrini E, Marrero D, et al. Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study. Nephrol Dial Transplant. 2012;27:417\u201322.","journal-title":"Nephrol Dial Transplant"},{"key":"1827_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/TP.0000000000000139","volume":"97","author":"G Opelz","year":"2014","unstructured":"Opelz G, Dohler B. Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers. Transplantation. 2014;97:310\u20135.","journal-title":"Transplantation"},{"key":"1827_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.kint.2018.03.013","volume":"94","author":"A Karaboyas","year":"2018","unstructured":"Karaboyas A, Xu H, Morgenstern H, Locatelli F, Jadoul M, Nitta K, et al. DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients. Kidney Int. 2018;94:589\u201398.","journal-title":"Kidney Int"},{"key":"1827_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2215\/CJN.07831109","volume":"5","author":"DJ Tai","year":"2010","unstructured":"Tai DJ, Lim TW, James MT, Manns BJ, Tonelli M, Hemmelgarn BR, et al. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol. 2010;5:623\u201330.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1827_CR23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"1827_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ajt.12590","volume":"14","author":"M Haas","year":"2014","unstructured":"Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272\u201383.","journal-title":"Am J Transplant"},{"key":"1827_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41\u201355.","journal-title":"Biometrika"},{"key":"1827_CR26","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.0006-341X.1999.00580.x","volume":"55","author":"M Parzen","year":"1999","unstructured":"Parzen M, Lipsitz SR. A global goodness-of-fit statistic for Cox regression models. Biometrics. 1999;55:580\u20134.","journal-title":"Biometrics"},{"key":"1827_CR27","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D'Agostino Jr","year":"1998","unstructured":"D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265\u201381.","journal-title":"Stat Med"},{"key":"1827_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1053\/j.ajkd.2016.08.018","volume":"69","author":"S Hiremath","year":"2017","unstructured":"Hiremath S, Fergusson DA, Fergusson N, Bennett A, Knoll GA. Renin\u2013angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2017;69:78\u201386.","journal-title":"Am J Kidney Dis"},{"key":"1827_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1034\/j.1399-0012.2003.02042.x","volume":"17","author":"A Oliveras","year":"2003","unstructured":"Oliveras A, Roquer J, Puig JM, Rodriguez A, Mir M, Orfila MA, et al. Stroke in renal transplant recipients: epidemiology, predictive risk factors and outcome. Clin Transplant. 2003;17:1\u20138.","journal-title":"Clin Transplant"},{"key":"1827_CR30","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1097\/00007890-200206270-00013","volume":"73","author":"RJ Howard","year":"2002","unstructured":"Howard RJ, Patton PR, Reed AI, Hemming AW, Van der Werf WJ, Pfaff WW, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation. 2002;73:1923\u20138.","journal-title":"Transplantation"},{"key":"1827_CR31","first-page":"521","volume":"18","author":"C Ponticelli","year":"2005","unstructured":"Ponticelli C, Campise MR. Neurological complications in kidney transplant recipients. J Nephrol. 2005;18:521\u20138.","journal-title":"J Nephrol"},{"key":"1827_CR32","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1097\/HJH.0000000000000378","volume":"32","author":"C Thomopoulos","year":"2014","unstructured":"Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32:2285\u201395.","journal-title":"J Hypertens"},{"key":"1827_CR33","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","volume":"358","author":"Group PC","year":"2001","unstructured":"Group PC. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033\u201341.","journal-title":"Lancet"},{"key":"1827_CR34","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995\u20131003.","journal-title":"Lancet"},{"key":"1827_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.atherosclerosis.2014.06.011","volume":"236","author":"P Clancy","year":"2014","unstructured":"Clancy P, Koblar SA, Golledge J. Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation. Atherosclerosis. 2014;236:108\u201315.","journal-title":"Atherosclerosis"},{"key":"1827_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1124\/jpet.112.197483","volume":"344","author":"A Alhusban","year":"2013","unstructured":"Alhusban A, Kozak A, Ergul A, Fagan SC. AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. J Pharmacol Exp Ther. 2013;344:348\u201359.","journal-title":"J Pharmacol Exp Ther"},{"key":"1827_CR37","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/HJH.0b013e3282f2dac9","volume":"26","author":"M Krikov","year":"2008","unstructured":"Krikov M, Thone-Reineke C, Muller S, Villringer A, Unger T. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF\/TrkB system in rats. J Hypertens. 2008;26:544\u201352.","journal-title":"J Hypertens"},{"key":"1827_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.phrs.2017.06.017","volume":"125","author":"JM Saavedra","year":"2017","unstructured":"Saavedra JM. Beneficial effects of angiotensin II receptor blockers in brain disorders. Pharmacol Res. 2017;125:91\u2013103.","journal-title":"Pharmacol Res"},{"key":"1827_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/bs.vh.2017.02.001","volume":"105","author":"YC Kim","year":"2017","unstructured":"Kim YC, Mungunsukh O, Day RM. Erythropoietin regulation by angiotensin II. Vitam Horm. 2017;105:57\u201377.","journal-title":"Vitam Horm"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-019-01827-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-019-01827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T00:09:24Z","timestamp":1608854964000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-019-01827-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,26]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1827"],"URL":"https:\/\/doi.org\/10.1007\/s10157-019-01827-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2019,12,26]]},"assertion":[{"value":"1 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None of the authors has any of conflict of interest to declare with regard to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (IRB approval number UMIN000033449) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Because data were retrospectively obtained from medical records, IRB waived the requirement for informed consent from the patients according to the ethical guidelines for medical and health research involving human subjects in Japan.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}